Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Stack, Anthony, Levy, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510013/
https://www.ncbi.nlm.nih.gov/pubmed/31110735
http://dx.doi.org/10.1002/ccr3.2142
_version_ 1783417366581870592
author Stack, Anthony
Levy, Isaac
author_facet Stack, Anthony
Levy, Isaac
author_sort Stack, Anthony
collection PubMed
description BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresectable BI‐ALCL, which was successfully treated with brentuximab vedotin.
format Online
Article
Text
id pubmed-6510013
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65100132019-05-20 Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma Stack, Anthony Levy, Isaac Clin Case Rep Case Reports BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresectable BI‐ALCL, which was successfully treated with brentuximab vedotin. John Wiley and Sons Inc. 2019-04-11 /pmc/articles/PMC6510013/ /pubmed/31110735 http://dx.doi.org/10.1002/ccr3.2142 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Stack, Anthony
Levy, Isaac
Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title_full Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title_fullStr Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title_full_unstemmed Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title_short Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
title_sort brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510013/
https://www.ncbi.nlm.nih.gov/pubmed/31110735
http://dx.doi.org/10.1002/ccr3.2142
work_keys_str_mv AT stackanthony brentuximabvedotinasmonotherapyforunresectablebreastimplantassociatedanaplasticlargecelllymphoma
AT levyisaac brentuximabvedotinasmonotherapyforunresectablebreastimplantassociatedanaplasticlargecelllymphoma

Ejemplares similares